Biocon Ltd. — Board/Management Information 2023

Sep 18, 2023

==> picture [136 x 53] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/AJ/2023-24/91

September 18, 2023

To, To, The Manager The Manager BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Mumbai – 400 050 Scrip Code – 532523 Scrip Symbol - BIOCON

Subject: Press Release �tled “Biocon Board Appoints Peter Bains as Group CEO”

Dear Sir/Madam,

“Biocon Board Appoints Peter Bains as Group CEO”.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

MAYA Digitally signed by MAYANK NK VERMA Date: 2023.09.18 VERMA 17:54:45 +05'30' _______

Mayank Verma Company Secretary and Compliance Officer Membership No.: ACS 18776

Enclosed: Press Release

==> picture [80 x 30] intentionally omitted <==

==> picture [122 x 27] intentionally omitted <==

PRESS RELEASE

Biocon Board Appoints Peter Bains as Group CEO

Bengaluru, Karnataka, India: September 18, 2023:

Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, announced today, that its Board has approved the appointment of Mr Peter Bains as the Group CEO, with effect from September 18th, 2023. He will be reporting directly to Biocon Group Chairperson, Ms Kiran Mazumdar-Shaw.

Prior thereto Mr. Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect, to assume this strategic executive responsibility.

Welcoming this appointment, Ms Kiran Mazumdar-Shaw said:

"Biocon is entering a dynamic phase of growth for its 3 core businesses, Biocon Biologics, Biocon Generics and Syngene, and for the Group as a whole.

I am delighted to welcome Peter to the Biocon Group in the role of Group CEO. Siddharth Mittal, CEO & MD Biocon Limited, Shreehas Tambe, CEO & MD Biocon Biologics Limited and Jonathan Hunt, CEO & MD Syngene International Limited will continue to have independent charge of their businesses and will work with Peter to strengthen synergistic strategic leadership at a Group level to maximise the combined value of all 3 businesses.

Peter has a unique fit and profile for the role having both extensive global leadership experience and success across the biopharmaceutical field and a comprehensive understanding of the Biocon Group, having led Syngene for 5 years, taking it through its very successful IPO in 2015.

I am confident that this appointment will serve the integrated business objectives of the Biocon Group of companies and deliver added value to all stakeholders.”

About Biocon Limited:

Biocon Limited , publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website : www.biocon.com; Follow-us on Twitter : @bioconlimited for company updates.

1

==> picture [80 x 30] intentionally omitted <==

==> picture [122 x 27] intentionally omitted <==

Biocon Biologics Ltd. (BBL) , a subsidiary of Biocon Ltd., is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to high quality biosimilars for millions of patients worldwide. It is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world- class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.

Website : www.bioconbiologics.com; Follow us on Twitter : @BioconBiologics for company updates.

therapeutics while improving healthcare outcomes. Website: www.bioconbiologics.com;Follow us on Twitter: @BioconBiologics for company updates.	therapeutics while improving healthcare outcomes. Website: www.bioconbiologics.com;Follow us on Twitter: @BioconBiologics for company updates.
FOR MORE INFORMATION
MEDIA	INVESTORS
Biocon Group & Biocon Biologics Seema Ahuja Global Head of Corporate Brand & Communications +91 99723 17792  seema.ahuja@biocon.com	Biocon Saurabh Paliwal Head - Investor Relations +91 95383 80801  saurabh.paliwal@biocon.com

2